Long awaited results from INTerpath-001, the first Phase 3 trial to demonstrate efficacy of a personalized mRNA therapy! Intismeran met key endpoints in melanoma $MRNA $MRK A pi…

Ruben Sebastian· @RubenSebas_ · X·2026-10-23 04:52· 15 hours agoScore60

Body · original

Long awaited results from INTerpath-001, the first Phase 3 trial to demonstrate efficacy of a personalized mRNA therapy! Intismeran met key endpoints in melanoma $MRNA $MRK A pivotal advance in personalized medicine! #ESMO26 https://t.co/OU80OoG64L

Heat 0 · 0 likes · 0 replies · 0 reposts

Conference abstracts

LBA1NCT05933577matched by INTerpath-001

INTerpath-001 Read the abstract →

NCT05933577NCT05933577matched by INTerpath-001

INTerpath-001 Read the abstract →

Source: Ruben Sebastian · x.com